PALO ALTO, Calif., Feb. 5, 2020 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, announced today that a
presentation of additional clinical study data on its
investigational therapy KSI-301 will be made at the Angiogenesis,
Exudation, and Degeneration 2020 meeting being held on February 8, 2020, in Miami, Florida.
"We are planning to present new safety, efficacy and durability
data on over 400 injections in 130 patients," said Victor Perlroth, M.D., Chief Executive Officer
of Kodiak Sciences. "Previously, we announced remarkable
biological durability and safety of KSI-301 in treatment naïve
patients across the three retinal diseases of wet AMD, Diabetic
Macular Edema and Retinal Vein Occlusion. The clinical data
continue to mature nicely. Later this year we are planning to
initiate four additional pivotal clinical studies of KSI-301 with
the objective to file an initial BLA in 2022. We look forward to
Dr. Do's presentation and to engaging with the community on
our data and plans."
Details of the presentation are as follows:
Title: Update on Clinical Studies of KSI-301: A Novel
Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended
Durability in Wet AMD
Presenter: Diana V. Do, M.D., Professor of
Ophthalmology at Byers Eye Institute, Stanford
University School of Medicine, Stanford, CA
Presentation date and time: February 8, 2020;
2:52 PM ET
Kodiak plans to issue a press release relating to the data and
to post the slide presentation on the "Investors & Media"
section of Kodiak's website at http://ir.kodiak.com/ at the
beginning of Dr. Do's presentation.
About KSI-301
KSI-301 is an investigational anti-VEGF therapy built on the
Company's Antibody Biopolymer Conjugate, or ABC, Platform and is
designed to maintain potent and effective drug levels in ocular
tissues for longer than existing agents. Kodiak's objective with
KSI-301 is to develop a new first-line agent to improve outcomes
for patients with retinal vascular diseases and to enable earlier
treatment and prevention of vision loss for patients with diabetic
eye disease. The Company's DAZZLE pivotal study in patients with
treatment-naïve wet AMD was initiated in October 2019. Kodiak plans to initiate additional
pivotal studies of KSI-301 in 2020 in retinal vein occlusion,
diabetic macular edema and diabetic retinopathy. These studies are
anticipated to form the basis of the Company's initial and
supplemental BLAs to support potential approval and
commercialization. KSI-301 is being developed and is fully owned
globally by Kodiak Sciences Inc.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a clinical stage biopharmaceutical
company specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. Founded in 2009, we are focused
on bringing new science to the design and manufacture of next
generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our ABC Platform™ merges the fields
of antibody-based and chemistry-based therapies and is at the core
of Kodiak's discovery engine. Kodiak's lead product candidate,
KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being
developed for the treatment of retinal vascular diseases including
age-related macular degeneration, a leading cause of blindness in
elderly patients, and diabetic eye diseases, a leading cause of
blindness in working-age patients. Kodiak has leveraged its ABC
Platform to build a pipeline of product candidates in various
stages of development including KSI-501, our bispecific
anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component, and we
are expanding our early research pipeline to include ABC Platform
based triplet inhibitors for multifactorial retinal diseases such
as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please
visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include, but are not limited to,
statements regarding future development plans, including plans to
initiate four additional pivotal clinical studies of KSI-301 and
expectations regarding the timing and filing of an initial BLA.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as "may," "will," "should,"
"would," "expect," "plan," "believe," "intend," "pursue," and other
similar expressions among others. Any forward-looking statements
are based on management's current expectations of future events and
are subject to a number of risks and uncertainties, including those
discussed in the section entitled "Risk Factors" in our most recent
Form 10-Q, as well as in our subsequent filings with the Securities
and Exchange Commission. These forward-looking statements speak
only as of the date hereof and Kodiak undertakes no obligation to
update forward-looking statements, and readers are cautioned not to
place undue reliance on such forward-looking statements.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentation-of-additional-ksi-301-phase-1b-clinical-study-data-at-angiogenesis-exudation-and-degeneration-2020-meeting-300999743.html
SOURCE Kodiak Sciences Inc.